As of the most recent check, Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock was up 25.91% to trade at $39.60 on the charts, showing signs of strength. Praxis’s stock has increased following the publishing of a business update.
Praxis (PRAX) has given an update on its portfolio and anticipated major events for 2024. Phase 2a PPR study topline data for PRAX-628 are anticipated in the first quarter of 2024, and the Phase 2b trial on focal epilepsy is anticipated to begin in the same year.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The second half of 2024 will see the topline findings of both Phase 3 trials assessing ulixacaltamide in essential tremor. Finalize regulatory relationships to move elsunersen (PRAX-222) in the direction of a crucial investigation for the management of developmental epilepsies caused by SCN2A gain-of-function (GOF).
Results from the first half of 2024’s Phase 2 EMBOLD investigation of PRAX-562 in developing epilepsies of SCN2A and SCN8A. Praxis is beginning 2023 with four products in the clinic: ulixacaltamide, the main program, and PRAX-628, which keeps demonstrating its promise as a best-in-class epileptic medication.
Praxis is building on the progress of an exciting 2023. PRAX’s dedication to achieving the worldwide benefit of its initiatives is demonstrated by the newly disclosed collaboration with Tenacia, which expands the availability of ulixacaltamide to Greater China.
Over a million Americans suffer from focal epilepsy; Praxis made significant advancements in developing PRAX-628 to treat this condition. PRAX-628 has an excellent tolerability characteristic, a potentially broad therapeutic index, and it can achieve effective concentrations in less than a day, according to preliminary research.
Praxis is carrying up a Phase 2a PPR trial to assess PRAX-628’s effectiveness in two cohorts at doses of 15 mg and 45 mg. PPR studies, which assess EEG signatures following sporadic photic stimulation, are frequently employed to help determine dosage and serve as a gauge of anti-seizure effectiveness. Numerous innovative and licensed medicines have validated this strategy.
